BACKGROUND: Several North American studies have observed survival benefit in patients exposed to β-blockers following traumatic brain injury (TBI). The purpose of this study was to evaluate the effect of β-blockade on mortality in a Swedish cohort of isolated severe TBI patients. METHODS: The trauma registry of an urban academic trauma center was queried to identify patients with an isolated severe TBI between 1/2007 and 12/2011. Isolated severe TBI was defined as an intracranial injury with an Abbreviated Injury Scale (AIS)≥3 excluding extra-cranial injuries AIS≥3. Multivariable logistic regression analysis was used to determine the effect of β-blocker exposure on mortality. Also, a subgroup analysis was performed to investigate the risk of mortality in patients on pre-admission β-blocker versus not and the effect of specific type of β-blocker on the overall outcome. RESULTS: Overall, 874 patients met the study criteria. Of these, 33% (n=287) were exposed to β-blockers during their hospital admission. The exposed patients were older (62±16 years vs. 49±21 years, p<0.001), and more severely injured based on their admission GCS, ISS, and head AIS scores (GCS≤8: 32% vs. 28%, p=0.007; ISS≥16: 71% vs. 59%, p=0.001; head AIS≥4: 60% vs. 45%, p<0.001). The crude mortality was higher in patients who did not receive β-blockers (17% vs. 11%, p=0.007) during their admission. After adjustment for significant confounders, the patients not exposed to β-blockers had a 5-fold increased risk of in-hospital mortality (AOR 5.0, CI 95% 2.7-8.5, p=0.001). No difference in survival was noted in regards to the type of β-blocker used. Subgroup analysis revealed a higher risk of mortality in patients naive to β-blockers compared to those on pre-admission β-blocker therapy (AOR 3.0 CI 95% 1.2-7.1, p=0.015). CONCLUSIONS: β-blocker exposure after isolated severe traumatic brain injury is associated with significantly improved survival. We also noted decreased mortality in patients on pre-admission β-blocker therapy compared to patients naive to such treatment. Further prospective studies are warranted.
BACKGROUND: Several North American studies have observed survival benefit in patients exposed to β-blockers following traumatic brain injury (TBI). The purpose of this study was to evaluate the effect of β-blockade on mortality in a Swedish cohort of isolated severe TBIpatients. METHODS: The trauma registry of an urban academic trauma center was queried to identify patients with an isolated severe TBI between 1/2007 and 12/2011. Isolated severe TBI was defined as an intracranial injury with an Abbreviated Injury Scale (AIS)≥3 excluding extra-cranial injuries AIS≥3. Multivariable logistic regression analysis was used to determine the effect of β-blocker exposure on mortality. Also, a subgroup analysis was performed to investigate the risk of mortality in patients on pre-admission β-blocker versus not and the effect of specific type of β-blocker on the overall outcome. RESULTS: Overall, 874 patients met the study criteria. Of these, 33% (n=287) were exposed to β-blockers during their hospital admission. The exposed patients were older (62±16 years vs. 49±21 years, p<0.001), and more severely injured based on their admission GCS, ISS, and head AIS scores (GCS≤8: 32% vs. 28%, p=0.007; ISS≥16: 71% vs. 59%, p=0.001; head AIS≥4: 60% vs. 45%, p<0.001). The crude mortality was higher in patients who did not receive β-blockers (17% vs. 11%, p=0.007) during their admission. After adjustment for significant confounders, the patients not exposed to β-blockers had a 5-fold increased risk of in-hospital mortality (AOR 5.0, CI 95% 2.7-8.5, p=0.001). No difference in survival was noted in regards to the type of β-blocker used. Subgroup analysis revealed a higher risk of mortality in patients naive to β-blockers compared to those on pre-admission β-blocker therapy (AOR 3.0 CI 95% 1.2-7.1, p=0.015). CONCLUSIONS: β-blocker exposure after isolated severe traumatic brain injury is associated with significantly improved survival. We also noted decreased mortality in patients on pre-admission β-blocker therapy compared to patients naive to such treatment. Further prospective studies are warranted.
Authors: Thomas J Schroeppel; John P Sharpe; Louis J Magnotti; Jordan A Weinberg; L Paige Clement; Martin A Croce; Timothy C Fabian Journal: J Trauma Acute Care Surg Date: 2014-02 Impact factor: 3.313
Authors: Bryan A Cotton; Kimberly B Snodgrass; Sloan B Fleming; Robert O Carpenter; Clinton D Kemp; Patrick G Arbogast; John A Morris Journal: J Trauma Date: 2007-01
Authors: Saman Arbabi; Eric M Campion; Mark R Hemmila; Melissa Barker; Mary Dimo; Karla S Ahrns; Andreas D Niederbichler; Kyros Ipaktchi; Wendy L Wahl Journal: J Trauma Date: 2007-01
Authors: Thomas J Schroeppel; Peter E Fischer; Ben L Zarzaur; Louis J Magnotti; L Paige Clement; Timothy C Fabian; Martin A Croce Journal: J Trauma Date: 2010-10
Authors: Kenji Inaba; Pedro G R Teixeira; Jean-Stephane David; Linda S Chan; Ali Salim; Carlos Brown; Timothy Browder; Elizabeth Beale; Peter Rhee; Demetrios Demetriades Journal: J Am Coll Surg Date: 2007-11-26 Impact factor: 6.113
Authors: Aziz S Alali; Kaushik Mukherjee; Victoria A McCredie; Eyal Golan; Prakesh S Shah; James M Bardes; Susan E Hamblin; Elliott R Haut; James C Jackson; Kosar Khwaja; Nimitt J Patel; Satish R Raj; Laura D Wilson; Avery B Nathens; Mayur B Patel Journal: Ann Surg Date: 2017-12 Impact factor: 12.969
Authors: Vijay Krishnamoorthy; Monica S Vavilala; Nophanan Chaikittisilpa; Frederick P Rivara; Nancy R Temkin; Abhijit V Lele; Edward F Gibbons; Ali Rowhani-Rahbar Journal: Crit Care Med Date: 2018-06 Impact factor: 7.598
Authors: Ahmad Mohammad Ismail; Tomas Borg; Gabriel Sjolin; Arvid Pourlotfi; Sebastian Holm; Yang Cao; Per Wretenberg; Rebecka Ahl; Shahin Mohseni Journal: Trauma Surg Acute Care Open Date: 2020-07-29
Authors: F Hildebrand; H-C Pape; K Horst; H Andruszkow; P Kobbe; T-P Simon; G Marx; T Schürholz Journal: Eur J Trauma Emerg Surg Date: 2015-08-08 Impact factor: 3.693
Authors: R Ahl; E P Thelin; G Sjölin; B-M Bellander; L Riddez; P Talving; S Mohseni Journal: Eur J Trauma Emerg Surg Date: 2017-03-08 Impact factor: 3.693
Authors: Thomas J Schroeppel; John P Sharpe; Charles Patrick Shahan; Lesley P Clement; Louis J Magnotti; Marilyn Lee; Michael Muhlbauer; Jordan A Weinberg; Elizabeth A Tolley; Martin A Croce; Timothy C Fabian Journal: Trauma Surg Acute Care Open Date: 2019-08-18